Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) has announced a collaboration with MIM Software to enhance treatment planning software for its Alpha DaRT cancer therapy. This partnership aims to integrate MIM's software suite to support Alpha DaRT across multiple cancer indications and improve clinical trial integration. The collaborative effort seeks to harness MIM's advanced imaging capabilities to optimize treatment planning, enhancing patient outcomes. Notably, recent data from U.S. clinical trials showed a 100% complete response rate in skin cancer treatments at 12 and 24 weeks post-therapy.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) will host a hybrid key opinion leader meeting on July 18, 2022, in New York, discussing its innovative Alpha DaRT cancer therapy. KOLs will present insights on the technology, highlighting recent clinical trials and upcoming studies, including a pivotal trial for recurrent cutaneous Squamous Cell Carcinoma. The Alpha DaRT technology employs radium-224 to target tumors with short-range alpha radiation, aiming to destroy cancer cells while sparing surrounding healthy tissue. This meeting presents a crucial opportunity for stakeholders to engage with industry experts.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced the treatment of its first patient in a feasibility study for the Alpha DaRT™ therapy in prostate cancer at Rambam Health Care Center, Haifa, Israel. The study aims to assess the feasibility and safety of Alpha DaRT as a neoadjuvant therapy before surgery, involving up to 10 patients. Following Alpha DaRT source insertion, surgical resection is scheduled 50 days later. CEO Uzi Sofer emphasized the significance of this milestone in expanding treatment applications beyond superficial cancers.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced the Israeli Ministry of Environmental Protection has granted an active radioactive license for Thorium-228 and Radium-224, allowing a shift to the main production floor in Jerusalem. This move will increase production capacity nearly threefold to approximately 90,000 Alpha DaRT sources annually, with future plans to apply for further increases. Additionally, the Massachusetts Department of Public Health has amended the license for Alpha Tau's subsidiary, tripling the Thorium-228 capacity from 10 milliCurie to 30 milliCurie, supporting increased production in the U.S.
Alpha Tau Medical (Nasdaq: DRTS) has announced conditional approval from the U.S. FDA for its Investigational Device Exemption (IDE) to initiate a pivotal study of its alpha-radiation therapy, Alpha DaRT™, for recurrent cutaneous Squamous Cell Carcinoma (SCC). The study will enroll up to 86 patients at 20 U.S. institutions and focus on those who have not responded to standard care. This is a significant milestone for Alpha Tau as it seeks to bring its innovative treatment to market.
On June 7, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS) announced the resignation of board member Gary Leibler, effective immediately. His departure is cited as unrelated to the company’s performance. CEO Uzi Sofer expressed gratitude for Leibler’s significant contributions since the company's inception. Despite his resignation, Leibler remains optimistic about Alpha Tau’s prospects, especially following its successful NASDAQ public listing, which provided essential capital for advancing its innovative Alpha DaRT cancer treatment technology.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) reported its first quarter 2022 financial results and updated on corporate milestones. The company raised approximately $104 million through its public debut in March 2022 and plans to initiate a pivotal U.S. trial for skin cancers mid-2022. Key highlights include a complete response rate of 100% in a pilot study for malignant skin cancer and significant advancements in manufacturing and supply chain capabilities. However, the company reported a net loss of $25.7 million, or ($0.54) per share, and expects its cash balance of $107 million to sustain operations for two years.
Alpha Tau Medical (Nasdaq: DRTS) has commenced treatment of its first patients in a French multicenter trial utilizing its innovative alpha-radiation therapy, Alpha DaRT™, for skin cancer. The trial, led by Dr. Pascal Pommier at the Leon Berard Center in Lyon, includes two cohorts focusing on newly diagnosed patients and those with recurrent disease. The main goal is to evaluate the overall response rate after treatment. CEO Uzi Sofer expressed excitement over the study, aiming to provide new treatment options for patients with limited alternatives.
On March 28, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) reported its 2021 financial results, highlighting a significant 100% complete response rate in its U.S. pilot trial for skin cancer. The company received two FDA breakthrough device designations and successfully completed its merger with Healthcare Capital Corp, raising approximately $90 million. R&D expenses increased to $11.4 million, resulting in a net loss of $27.3 million for the year. As of December 31, 2021, Alpha Tau's cash reserves stood at $31.9 million, expected to sustain operations for two years.